Keryx Biopharmaceuticals Announces U.S. FDA Filing Acceptance of Supplemental New Drug Application for Auryxia® (ferric citrate) Tablets
08. März 2017 07:30 ET
|
Keryx Biopharmaceuticals, Inc.
BOSTON, March 08, 2017 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today...
Keryx Biopharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial Results
01. März 2017 07:00 ET
|
Keryx Biopharmaceuticals, Inc.
Fourth quarter and Full Year 2016 Auryxia® (ferric citrate) net U.S. product sales of $8.2 million and $27.2 million, respectively Early 2017 Auryxia prescription demand showing positive momentum and...
Keryx Biopharmaceuticals to Webcast its Presentations at Two Investor Conferences in March 2017
23. Februar 2017 08:31 ET
|
Keryx Biopharmaceuticals, Inc.
BOSTON, Feb. 23, 2017 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc., (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today...
Keryx Biopharmaceuticals to Host Conference Call of Fourth Quarter and Full Year 2016 Financial Results on Wednesday, March 1, 2017
16. Februar 2017 09:15 ET
|
Keryx Biopharmaceuticals, Inc.
BOSTON, Feb. 16, 2017 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to market for people with renal disease,...
Keryx Biopharmaceuticals to Webcast its Presentation at RBC Capital Markets' 2017 Global Healthcare Conference on February 22, 2017
08. Februar 2017 09:01 ET
|
Keryx Biopharmaceuticals, Inc.
BOSTON, Mass., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease,...
Keryx Biopharmaceuticals Announces Publication of Auryxia® (ferric citrate) Phase 3 Trial Results for Iron Deficiency Anemia (IDA) in Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) in Journal of the American Society of Nephrology
12. Januar 2017 09:53 ET
|
Keryx Biopharmaceuticals, Inc.
BOSTON, Jan. 12, 2017 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today...
Keryx Biopharmaceuticals Announces Recent Business Progress and Reviews Corporate Strategy at 35th Annual J.P. Morgan Healthcare Conference
08. Januar 2017 18:00 ET
|
Keryx Biopharmaceuticals, Inc.
Enters 2017 with positive momentum for Auryxia® (ferric citrate) in dialysis; preliminary unaudited fourth quarter net U.S. product sales of $8.2 millionSubmitted supplemental new drug application...
Keryx Biopharmaceuticals to Webcast its Presentation at J.P. Morgan’s 35th Annual Healthcare Conference on January 11, 2017
22. Dezember 2016 08:31 ET
|
Keryx Biopharmaceuticals, Inc.
BOSTON, Dec. 22, 2016 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today...
Keryx Biopharmaceuticals Announces Case Study Data of Auryxia® Presented at ASN’s Kidney Week
18. November 2016 10:31 ET
|
Keryx Biopharmaceuticals, Inc.
CHICAGO, Nov. 18, 2016 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today...
Keryx Biopharmaceuticals Announces Multiple Scientific Presentations of Phase 3 Trial Results of Ferric Citrate for Iron Deficiency Anemia (IDA) in Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD)
17. November 2016 10:31 ET
|
Keryx Biopharmaceuticals, Inc.
Pivotal Phase 3 data showed the potential of Ferric Citrate (Auryxia®) to treat IDA in adults with NDD-CKD Phase 3 trial results support supplemental new drug application (sNDA) seeking to...